Evidence map›Paper›PMID 40455292›Full record

ArticleActa neuropathologica2025

Anti-pyroglutamate-3 Aβ immunotherapy engages microglia and inhibits amyloid accumulation in transgenic mouse models of Aβ amyloidosis.

Fan Liao, Maria Calvo-Rodriguez, Meha Chhaya, Julian P Sefrin, Erik I Charych, Mario Mezler, Diana Clausznitzer, Emily J McGlame, Karen Zhao, Allison Rodgers and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. A randomized phase 1b/2 trial of ABBV-916 in adults with early Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Trial
  2. Trial
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Fan LiaoAbbVie, Cambridge Research Center, 200 Sidney Street, Cambridge, MA, 02139, USA. fan.liao@abbvie.com.
Maria Calvo-RodriguezAbbVie, Cambridge Research Center, 200 Sidney Street, Cambridge, MA, 02139, USA.
Meha ChhayaAbbVie Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA.
Julian P SefrinAbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061, Ludwigshafen, Germany.
Erik I CharychAbbVie, Cambridge Research Center, 200 Sidney Street, Cambridge, MA, 02139, USA.
Mario MezlerAbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061, Ludwigshafen, Germany.
Diana ClausznitzerAbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061, Ludwigshafen, Germany.
Emily J McGlameAbbVie, Cambridge Research Center, 200 Sidney Street, Cambridge, MA, 02139, USA.
Karen ZhaoAbbVie, Cambridge Research Center, 200 Sidney Street, Cambridge, MA, 02139, USA.
Allison RodgersAbbVie, Cambridge Research Center, 200 Sidney Street, Cambridge, MA, 02139, USA.
Yang CaoAbbVie, Cambridge Research Center, 200 Sidney Street, Cambridge, MA, 02139, USA.
Philipp F SeckerAbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061, Ludwigshafen, Germany.
Laura Fernandez Garcia-AgudoAbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061, Ludwigshafen, Germany.
Lili HuangAbbVie Bioresearch Center, 100 Research Drive, Worcester, MA, 01605, USA.
Corinna KleinAbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061, Ludwigshafen, Germany.
Tammy DellovadeAbbVie, Cambridge Research Center, 200 Sidney Street, Cambridge, MA, 02139, USA.
Eric KarranAbbVie, Cambridge Research Center, 200 Sidney Street, Cambridge, MA, 02139, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer disease (AD) is the most common form of dementia affecting more than 6 million people in the United States. Currently, 3 monospecific antibodies targeting different Amyloid β (Aβ) species have been approved by the US FDA as disease modifying therapeutics for treatment in early AD patients with amyloid pathology. ABBV-916 is a clinical stage human IgG1 monoclonal antibody which binds to N-terminal truncated, pyroglutamate-modified at amino acid position 3, Aβ (Aβ

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAmyloidosisAntibodies, MonoclonalImmunotherapyMicrogliaPeptide FragmentsAmyloid beta-Protein PrecursorAnimalsBrainDisease Models, AnimalFemaleHumansMiceMice, TransgenicPlaque, AmyloidAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAntibodies, MonoclonalPeptide FragmentsAlzheimer’s DiseaseAmyloidMicrogliaPassive immunotherapyTwo-photon microscopy

Identifiers

PMID40455292
PMCPMC12130127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.